On September 7, 2021, Hinova Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases through targeted protein degradation technologies, announced that the National Medical Products Administration (NMPA) had accepted its application for clinical trials of HP558 injection.

HP558 is a First-in-class CD44v6 inhibitor developed by Amcure GmbH in Germany and licenced by Hinova. Hinova has exclusive rights to develop and commercialize HP558 in China (including Hong Kong, Macao and Taiwan) for all indications.

The Phase I clinical trial of HP558 has been completed in Europe, and no drugs with the same target for the same indication have entered clinical trials worldwide. Preclinical and clinical trials have shown that HP558 has good antitumor activity, safety and tolerability, and has potential therapeutic effects in gastrointestinal tumors. It can also be used in combination with chemotherapy or other target therapy agents for the treatment of a variety of advanced tumors. 

About Hinova

Hinova is an international and clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases. Hinova has committed to the discovery and development of innovative medicines for patients globally through deuteration and targeted protein degradation technologies.